BlackRock, Inc. 13D and 13G filings for Arrowhead Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-01-23 4:14 pm Purchase |
2023-12-31 | 13G | Arrowhead Pharmaceuticals, Inc. ARWR |
BLACKROCK INC BLK |
13,303,281 12.400% |
592,650 (+4.66%) |
Filing |
| 2023-01-26 08:52 am Unchanged |
2022-12-31 | 13G | Arrowhead Pharmaceuticals, Inc. ARWR |
BLACKROCK INC BLK |
12,710,631 12.000% |
0 (Unchanged) |
Filing |
| 2023-01-20 09:43 am Purchase |
2022-12-31 | 13G | Arrowhead Pharmaceuticals, Inc. ARWR |
BLACKROCK INC BLK |
12,710,631 12.000% |
702,568 (+5.85%) |
Filing |
| 2022-01-27 11:00 am Unchanged |
2021-12-31 | 13G | Arrowhead Pharmaceuticals, Inc. ARWR |
BLACKROCK INC BLK |
12,008,063 11.500% |
0 (Unchanged) |
Filing |
| 2022-01-25 3:03 pm Sale |
2021-12-31 | 13G | Arrowhead Pharmaceuticals, Inc. ARWR |
BLACKROCK INC BLK |
12,008,063 11.500% |
-555,069 (-4.42%) |
Filing |
| 2021-01-26 6:52 pm Purchase |
2020-12-31 | 13G | Arrowhead Pharmaceuticals, Inc. ARWR |
BLACKROCK INC BLK |
12,563,132 12.200% |
202,174 (+1.64%) |
Filing |